JAC Advance Access originally published online on December 6, 2007
Journal of Antimicrobial Chemotherapy 2008 61(2):235-237; doi:10.1093/jac/dkm476
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading articles |
Tissue concentrations: do we ever learn?
1 Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands 2 Center for Anti-Infective Agents, Vienna, Austria 3 Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 4 Cellular and Molecular Pharmacology Unit, Université catholique de Louvain, Brussels, Belgium 5 Department of Pharmaceutics, University of Florida, Gainesville, FL, USA 6 Department of Medical Sciences, Infectious Diseases, Uppsala University, Uppsala, Sweden
* Corresponding author. Tel: +31-24-3657514; Fax: +31-24-3657516; E-mail: mouton{at}cwz.nl
 |
Abstract |
|---|
Over the last decades, numerous papers have appeared—and still are appearing—that describe concentrations in tissues in an effort to predict the efficacy of an antimicrobial agent based on these concentrations and MICs for microorganisms. A common method is to use measurements of concentrations in tissue homogenates, comparing these with values derived from the corresponding blood samples and on that basis draw conclusions with respect to the potential clinical use of the drug. This approach is not justifiable for a number of reasons that includes both pharmacokinetic as well as pharmacodynamic causes. This way of presenting data with the derived conclusions is often misleading and may ultimately be harmful in patient care.
Keywords: homogenizing , tissue distribution , pharmacodynamics , pharmacokinetics
|
Introduction |
|---|
Over the last decades, studies have been performed that describe whole tissue concentrations of antimicrobials derived from homogenates. In a number of these the authors subsequently use the results to draw conclusions towards the activity and efficacy of the drug.1–6 Measuring concentrations in tissue homogenates, comparing them with the corresponding blood samples and recommending the drug for clinical use based on such pharmacokinetic data, is not justifiable as has been shown more then 25 years ago.7 We consider this way of presenting data with its derived conclusions misleading and, because erroneous conclusions may be drawn with respect to the activity of the drug, also potentially harmful in patient care.
In the following, we briefly provide the scientific basis for our arguments and show a number of examples to underscore our point of view based on current knowledge on concentrations at the site of infection.
|
What do tissue concentrations represent? |
|---|
Whole tissue concentrations are usually obtained by grinding up (homogenizing) or lysing tissue and subsequently determining the concentration of the antibiotic in the tissue homogenate. However, this does not take into account the fact that tissues are made of distinct compartments (interstitial fluid, cells, and within cells the various subcellular organelles) in which the drug is not necessarily distributed in a homogeneous fashion. Moreover, measurements in tissue homogenates do not give any information on whether the drug is actually available for activity. Thus, when whole tissue concentrations are determined by measuring the overall concentration in the tissue homogenate, the concentrations found are not informative with respect to the (active) concentration of the antimicrobial at the site of infection.7–9 Since most bacterial infections are located in the extracellular compartment, those concentrations are of primary interest. If a compound is distributed mainly extracellularly, such as β-lactams and aminoglycosides, grinding up the tissue means dilution of the drug by mixing intracellular and extracellular fluids, resulting in underestimation of its concentrations at the site of infection. Conversely, if drugs are accumulated by cells (such as fluoroquinolones or macrolides), assay of total tissue levels will lead to gross overestimation of the extracellular concentration. The opposite is true for intracellular infections.
|
Pharmacokinetic relationships between serum and tissue concentrations |
|---|
After administration, an antibiotic (as any drug) becomes distributed into various compartments in the body. The pharmacokinetics of most antibiotics can be described by either a two or a three compartment model, and the amount of drug transferred between compartments is described by intercompartmental clearance. The equilibrium between the compartments does not occur instantaneously and the shape of the concentration–time curve in either compartment can therefore be markedly different.10 The reasons for the differences are delayed steady-state, time-lags to and from other compartments as documented in numerous studies, including those where concentrations have been determined in specific compartments.8,11–15 Depending on the time a whole tissue sample is taken (in most situations only once), any value of a ratio of tissue concentration versus serum concentration can be obtained. Figure 1 and Table 1 illustrate this by showing the concentration–time curves in serum and two tissue compartments and the ratio of serum to tissue concentration in these two compartments. To circumvent the problem, multiple samples would have to be taken in a steady-state situation using an appropriate technique in a single patient, which is often unpractical and even ethically questionable. Alternatively, samples could be taken at multiple time-points from different individuals, in both cases directly from the specified compartment, but this would introduce a large possibility for errors due to interindividual variabilities.
|
|
|
Pharmacokinetic/pharmacodynamic relationships |
|---|
 TopAbstractIntroductionWhat do tissue concentrations...Pharmacokinetic relationships... Pharmacokinetic/pharmacodynamic... When are tissue concentrations...ConclusionsTransparency declarationsReferences |
|---|
Pharmacokinetic/pharmacodynamic relationships have been described for a number of drugs, using serum concentrations as a surrogate for the concentrations at the actual site of infection. These relationships show a marked consistency, and the pharmacodynamic index values (such as AUC/MIC) that result in a certain effect have been determined for most classes of antibiotics.16,17 The pharmacokinetic/pharmacodynamic index values are derived from concentrations measured in serum over time and it is inappropriate to infer similar effects from tissue concentrations or local concentrations. Statements such as ‘concentrations in tissue x h after dosing are much higher than the MICs for common pathogens2,4 that cause disease' are meaningless.
The concentrations may have been lower or higher in relation to the serum concentrations, and the values of the denominator are therefore incorrect, while the drug exposure over time is not included either. If inferences are drawn from local concentrations, the concentration–effect relationships at the actual infection site should be used and these are usually unknown.
|
When are tissue concentrations of value? |
|---|
|
TopAbstractIntroductionWhat do tissue concentrations...Pharmacokinetic relationships...Pharmacokinetic/pharmacodynamic...When are tissue concentrations...ConclusionsTransparency declarationsReferences |
|---|
It is very difficult to determine the concentration of a drug at the site of the infection and/or at the receptor site. This is one of the reasons that the surrogate values in serum are being used. Although the results of using these surrogates are remarkably consistent, aberrations do occur, for instance unexpected failure or success of treatment. In those cases, concentrations at the site of infection, using a validated method, could certainly be of value. Measurements in specific compartments (such as epithelial lining fluid and CSF) or determining free concentrations in interstitial fluid by microdialysis contribute to our understanding of concentrations at the site of infection.18 It should be borne in mind, however, that all these methods may suffer from methodological problems that are not always immediately apparent. Finally, whole tissue concentrations can be of value in initial studies during drug development to determine the overall distribution of a drug.
|
Conclusions |
|---|
We conclude that, comparable to the expressions used by both the European Medicines Agency19 as well as the ASM,20 the use and determination of tissue concentrations derived from homogenates to draw direct conclusions on drug activity are unwarranted and/or unreliable.21,22 Statements that infer activity of the drug based on concentrations measured in relation to the susceptibility (MIC) of the agent should be avoided. Alternatively, measurements of concentrations in specified compartments may yield information that is much needed to understand the efficacy of an antimicrobial but should be supplemented with effective measures of activity and/or clinical evidence. In that respect, the use of unbound serum concentrations has proved to be useful as a surrogate correlate.23 Using concentrations in tissue-homogenates alone to determine exposure–response relationships and drawing conclusions with respect to clinical use are unjustified and may ultimately be harmful to patients.
|
Transparency declarations |
|---|
None to declare.
|
References |
|---|
1 Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother (2007) 60:819–23.
2
Boselli E, Breilh D, Djabarouti S, et al. Diffusion of ertapenem into bone and synovial tissues. J Antimicrob Chemother (2007) 60:893–6.
3
Wittau M, Wagner E, Kaever V, et al. Intraabdominal tissue concentration of ertapenem. J Antimicrob Chemother (2006) 57:312–6.
4
Shyu WC, Reilly J, Campbell DA, et al. Penetration of cefprozil into tonsillar and adenoidal tissues. Antimicrob Agents Chemother (1993) 37:1180–3.
5
Byl B, Jacobs F, Roucloux I, et al. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob Agents Chemother (1999) 43:681–2.
6
Muller-Serieys C, Soler P, Cantalloube C, et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother (2001) 45:3104–8.
7 Ryan DM, Cars O. Antibiotic assays in muscle: are conventional tissue levels misleading as indicator of the antibacterial activity? Scand J Infect Dis (1980) 12:307–9.[Web of Science][Medline]
8
Ryan DM, Cars O. A problem in the interpretation of β-lactam antibiotic levels in tissues. J Antimicrob Chemother (1983) 12:281–4.
9
Burkhardt O, Brunner M, Schmidt S, et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother (2006) 58:632–6.
10 Ryan DM, Cars O, Hoffstedt B. The use of antibiotic serum levels to predict concentrations in tissues. Scand J Infect Dis (1986) 18:381–8.[Web of Science][Medline]
11
Mouton JW, Horrevorts AM, Mulder PG, et al. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother (1990) 34:2307–11.
12 Nolting A, Costa TD, Vistelle R, et al. Determination of free extracellular concentrations of piperacillin by microdialysis. J Pharm Sci (1996) 85:369–72.[CrossRef][Web of Science][Medline]
13
Derendorf H. Pharmacokinetic evaluation of β-lactam antibiotics. J Antimicrob Chemother (1989) 24:407–13.
14
Cars O, Ryan DM. Determination of extravascular concentrations of doxycycline. J Antimicrob Chemother (1983) 12:277–9.
15 Tulkens PM. Intracellular pharmacokinetics and pharmacodynamics of antibiotics. Rev Pneumol Clin (1996) 52:S51–5.[Medline]
16 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 26:1–10. quiz 11–2.[Web of Science][Medline]
17 Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis (2007) 44:79–86.[CrossRef][Web of Science][Medline]
18 Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol (2007) 7:498–504.[CrossRef][Medline]
19 CHMP. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. (2000) London. http://www.emea.europa.eu/pdfs/human/ewp/265599en.pdf. Document CPMP/EWP/2655/99.
20 American Society for Microbiology. Instructions to authors. Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. (2007) www.icaac.org/topcat.asp.
21 Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand J Infect Dis Suppl (1990) 74:23–33.[Medline]
22
Muller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 48:1441–53.
23 Craig WA, Ebert SC. Protein binding and its significance in antibacterial therapy. Infect Dis Clin North Am (1989) 3:407–14.[Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Brown and A. MacGowan Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility J. Antimicrob. Chemother., February 1, 2010; 65(2): 183 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lemaire, F. Van Bambeke, P. C. Appelbaum, and P. M. Tulkens Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines J. Antimicrob. Chemother., November 1, 2009; 64(5): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. O. Gubbins, J. R. Amsden, S. A. McConnell, and E. J. Anaissie Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3664 - 3674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lemaire, F. Van Bambeke, and P. M. Tulkens Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in Human THP-1 Macrophages Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3734 - 3743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Roberts, C. M. J. Kirkpatrick, M. S. Roberts, T. A. Robertson, A. J. Dalley, and J. Lipman Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution J. Antimicrob. Chemother., July 1, 2009; 64(1): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barbour, S. Schmidt, S. N. Sabarinath, M. Grant, C. Seubert, D. Skee, B. Murthy, and H. Derendorf Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2773 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Landersdorfer, M. Kinzig, J. B. Bulitta, F. F. Hennig, U. Holzgrabe, F. Sorgel, and J. Gusinde Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by Population Pharmacokinetics and Monte Carlo Simulation Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2569 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Landersdorfer, M. Kinzig, F. F. Hennig, J. B. Bulitta, U. Holzgrabe, G. L. Drusano, F. Sorgel, and J. Gusinde Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2074 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Zeller, F. Durand, M.-D. Kitzis, L. Lhotellier, J.-M. Ziza, P. Mamoudy, and N. Desplaces Continuous Cefazolin Infusion To Treat Bone and Joint Infections: Clinical Efficacy, Feasibility, Safety, and Serum and Bone Concentrations Antimicrob. Agents Chemother., March 1, 2009; 53(3): 883 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marchand, D. Frasca, C. Dahyot-Fizelier, C. Breheret, O. Mimoz, and W. Couet Lung Microdialysis Study of Levofloxacin in Rats following Intravenous Infusion at Steady State Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3074 - 3077. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||